.png)
Movers & Shakers: Q3 & Q4 2021 - Life Science & CRO
Mantell Associates Life Sciences division works with the Biotech, Pharmaceutical and Contract Res...
Search by
Search by tags
.jpg)
Movers & Shakers: Q3 & Q4 2021 - Small Molecule CDMO
he Small Molecule CDMO team here at Mantell Associates is recognised as the 'go-to' partner with...
.jpg)
Movers & Shakers: Q3 & Q4 2021 - Large Molecule CDMO
The Large Molecule CDMO arm of Mantell Associates covers all appointments within Contract Develo...
Movers & Shakers: Q3 &Q4 2021 - Life Science Consulting
Mantell Associates Life Sciences division works with the Biotech, Pharmaceutical and Contract Re...
Neuroscience & The Pharmaceutical Industry
Neuroscience within the pharmaceutical and biotechnology industry has been a hugely controversia...
What the Future Holds for Cell and Gene Therapy
Unlike many other medical approaches, cell and gene therapies (CGTs) have the potential to be a o...
Drugs, Destruction, and Development: An analysis into the impact of the Ukraine invasion on the pharmaceutical industry
In the early dawn of February 24th, Russian President Vladimir Putin launched what was to become...
Should diversity be mandatory in U.K Clinical Trials?
The clinical trial industry has always struggled with diverse recruitment within their trials. O...
Digital Transformation in the Life Science Industry
Digital Transformation is developing new high tech ways or modifying existing systems to help a c...
Mantell Associates Network: Q&A with Kåre Engkilde
As part of the Mantell Associates Network podcast earlier last year, CEO Alessandro Mantell w...
Why the CRO market is expected to reach over $110 Billion by 2028
What is a CRO?A Contract Research Organization (CRO) offers a range of outsourcing services to B...
The Importance of Mergers & Acquisitions in Pharma
Mergers and Acquisitions play an instrumental role in growth strategies & development for al...
Mantell Associates Network: Q&A with Peter Worsöe
As part of the Mantell Associates Network podcast earlier last year, CEO Alessandro Mantell we...
How Neuralink is Shaping the Medical Device Industry in 2022
In 2021, I covered a lot of areas within the Medical Device market from Surgical, Diagnostics, L...
A Candidate Short Market
The term "candidate short" market means that there are more available positions than potential c...
My Journey at Mantell Associates - Vincent Mackay
I joined Mantell Associates as an Account Manager in October 2020.Before this I had been workin...
.png)
Five key market observations from 2021…
In 2021, I covered Large Molecule CDMO, making appointments from mid to senior level across almos...
.png)
My Journey at Mantell Associates - Nikhil Akkoo
I joined Mantell Associate (MA) in April 2021 in the midst of the UK lockdown.I graduated in Dece...
.png)
Women in Senior Leadership Positions
The ongoing debate surrounding women in seniority and management roles is an issue that has been...
.png)
Mantell Associates Network: Q&A with Jonas Skjødt Møller & Gregor Kawaletz
As part of the Mantell Associates Network podcast earlier last year, CEO Alessandro Mantell wel...